OMER - Omeros Rising: Prospects Income Expenses Spell Risk Overmatched By Opportunity
Omeros (OMER) is a clinical stage biotech that is in the midst of a pullback. I expect it to recover and will be watching for healthy returns once one of its Phase 3 candidates hauls in an FDA or EMA approval. In the meantime, Omeros presents a highly attractive speculative acquisition as I discuss below.
Omeros' pipeline has significant near-to-midterm revenue potential.
Omeros' lead compound (OMS721), as a generic recently named narsoplimab, is the lure that draws attention to this stock for those hoping for a big payday in the not too distant